ALDX - Aldeyra Therapeutics, Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
8.725
+0.025 (+0.29%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close8.700
Open8.750
Bid0.000 x 800
Ask0.000 x 800
Day's Range8.600 - 8.750
52 Week Range3.900 - 11.900
Volume99,865
Avg. Volume97,367
Market Cap171.576M
Beta1.91
PE Ratio (TTM)N/A
EPS (TTM)-1.403
Earnings DateAug 6, 2018 - Aug 10, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est19.80
Trade prices are not sourced from all markets
  • PR Newswire10 days ago

    Aldeyra Therapeutics Announces First Quarter 2018 Financial Results

    LEXINGTON, Mass. , May 15, 2018 /PRNewswire/ -- Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) (Aldeyra), a biotechnology company devoted to development of next-generation medicines to improve the lives of ...

  • ACCESSWIRE10 days ago

    Aldeyra Therapeutics, Inc. to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / May 15, 2018 / Aldeyra Therapeutics, Inc. (NASDAQ: ALDX ) will be discussing their earnings results in their Q1 Earnings Call to be held on May 15, 2018 at 8:00 AM Eastern Time. ...

  • PR Newswire15 days ago

    Aldeyra Therapeutics Appoints David McMullin as Senior Vice President, Corporate Development and Strategy

    LEXINGTON, Mass., May 10, 2018 /PRNewswire/ -- Aldeyra Therapeutics, Inc. (ALDX) (Aldeyra), a biotechnology company devoted to development of next-generation medicines to improve the lives of patients with immune-mediated diseases, announced the hiring of David McMullin to the newly created position of Senior Vice President, Corporate Development and Strategy.  Mr. McMullin will be responsible for leading Aldeyra's commercial planning, corporate development, and business development efforts. Mr. McMullin brings extensive experience leading business development, strategic planning, commercial and operational activities in the biopharmaceutical industry.

  • PR Newswire16 days ago

    Aldeyra Therapeutics Schedules Webcast and Conference Call to Provide First Quarter 2018 Financial Results

    LEXINGTON, Mass. , May 9, 2018 /PRNewswire/ -- Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) (Aldeyra), a biotechnology company devoted to development of next-generation medicines to improve the lives of patients ...

  • PR Newswire24 days ago

    Aldeyra Therapeutics Presents Dry Eye Disease Phase 2a Clinical Trial Results at the Association for Research in Vision and Ophthalmology 2018 Annual Meeting

    LEXINGTON, Mass., May 1, 2018 /PRNewswire/ -- Aldeyra Therapeutics, Inc. (ALDX) (Aldeyra), a biotechnology company devoted to development of next-generation medicines to improve the lives of patients with immune-mediated diseases, presented the results of a randomized, double-masked, parallel-group Phase 2a dry eye disease clinical trial of topical ocular reproxalap at the Association for Research in Vision and Ophthalmology (ARVO) 2018 Annual Meeting. The primary objective of the trial, to select a formulation for Phase 2b clinical testing, was achieved with the advancement of 0.1% reproxalap. Relative to baseline, dry eye disease patients treated with 0.1% reproxalap demonstrated statistically significant improvement from baseline in tear volume (Schirmer test) as well as statistically and clinically significant improvement in the Overall 4-Symptom Score and the Ocular Discomfort Score.

  • PR Newswirelast month

    Aldeyra Therapeutics Announces First Patient Enrolled in Allergic Conjunctivitis Phase 3 Clinical Trial

    LEXINGTON, Mass., April 24, 2018 /PRNewswire/ -- Aldeyra Therapeutics, Inc. (ALDX) (Aldeyra), a biotechnology company devoted to development of next-generation medicines to improve the lives of patients with inflammatory diseases, today announced that it has enrolled the first patient in a Phase 3 clinical trial of topical ocular reproxalap for the treatment of allergic conjunctivitis. "We are pleased to advance our allergic conjunctivitis program to Phase 3 clinical testing," commented Todd C. Brady, M.D., Ph.D., President and CEO of Aldeyra.  "With clinically demonstrated post-histaminic activity, reproxalap could represent the first mechanistically differentiated product in decades for the treatment of allergic conjunctivitis, a chronic disease that affects approximately 100 million patients in the United States.

  • ACCESSWIRElast month

    Free Post Earnings Research Report: Curis’ Quarterly Revenue Jumped 38.10%

    Stock Monitor: Aldeyra Therapeutics Post Earnings Reporting LONDON, UK / ACCESSWIRE / April 19, 2018 / Active-Investors.com has just released a free earnings report on Curis, Inc. (NASDAQ: CRIS ). If you ...

  • GlobeNewswire2 months ago

    Analysis: Positioning to Benefit within Euronet Worldwide, Innospec, Zosano Pharma, Ardelyx, Crown Castle International, and Aldeyra Therapeutics — Research Highlights Growth, Revenue, and Consolidated Results

    NEW YORK, April 05, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of ...

  • PR Newswire2 months ago

    Aldeyra Therapeutics Announces Year End 2017 Financial Results

    LEXINGTON, Mass. , March 29, 2018 /PRNewswire/ -- Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) (Aldeyra), a biotechnology company devoted to development of next-generation medicines to improve the lives of ...

  • ACCESSWIRE2 months ago

    Aldeyra Therapeutics, Inc. to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / March 29, 2018 / Aldeyra Therapeutics, Inc. (NASDAQ: ALDX ) will be discussing their earnings results in their Q4 Earnings Call to be held on March 29, 2018 at 8:00 AM Eastern ...

  • PR Newswire2 months ago

    Aldeyra Therapeutics Schedules Webcast and Conference Call to Provide Full Year 2017 Financial Results

    LEXINGTON, Mass. , March 22, 2018 /PRNewswire/ -- Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) (Aldeyra), a biotechnology company devoted to development of next-generation medicines to improve the lives of ...

  • PR Newswire3 months ago

    Aldeyra Therapeutics Announces Agreement with Johnson & Johnson Innovation to Advance Novel Immune-Modulating Drugs for Systemic Inflammatory Diseases

    LEXINGTON, Mass., Feb. 27, 2018 /PRNewswire/ -- Aldeyra Therapeutics, Inc. (ALDX) (Aldeyra), a biotechnology company devoted to development of next-generation medicines to improve the lives of patients with inflammatory diseases, today announced that it has entered into a collaborative research agreement with Janssen Research & Development, LLC (Janssen), one of the Janssen Pharmaceutical Companies of Johnson & Johnson. Aldeyra plans to collaborate with Janssen on the development of novel drugs designed to sequester pro-inflammatory aldehyde mediators, a new class of therapeutic targets. Aldeyra's aldehyde sequestration platform represents a novel therapeutic class, led by reproxalap, a first-in-class drug candidate that has demonstrated anti-inflammatory activity in four Phase 2 clinical trials.

  • PR Newswire3 months ago

    Aldeyra Therapeutics Selected for Podium Presentation of Phase 2a Dry Eye Disease Results at the 2018 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting

    Poster Presentations to Feature Phase 2b Allergic Conjunctivitis Results, in Addition to Activity of Reproxalap and ADX-103 in Models of Retinal Inflammation, Diabetic Macular Edema, and Dry Age-Related ...

  • PR Newswire4 months ago

    Aldeyra Therapeutics Announces First Patient Enrolled in Dry Eye Disease Phase 2b Clinical Trial

    LEXINGTON, Mass., Jan. 30, 2018 /PRNewswire/ -- Aldeyra Therapeutics, Inc. (ALDX) (Aldeyra), a clinical-stage biotechnology company devoted to treating inflammation and inborn errors of metabolism, today announced that it has enrolled the first patient in a Phase 2b clinical trial of topical ocular reproxalap for the treatment of dry eye disease (DED). The Phase 2b clinical trial will test two concentrations of topical reproxalap (0.1% and 0.25%) against vehicle over 12 weeks of treatment in 300 patients with moderate dry eye disease.

  • Why Aldeyra Therapeutics Inc’s (NASDAQ:ALDX) CEO Pay Matters To You
    Simply Wall St.5 months ago

    Why Aldeyra Therapeutics Inc’s (NASDAQ:ALDX) CEO Pay Matters To You

    Leading Aldeyra Therapeutics Inc (NASDAQ:ALDX) as the CEO, Todd Brady took the company to a valuation of USD$126.18M. Recognizing whether CEO incentives are aligned with shareholders is a crucial partRead More...

  • PR Newswire6 months ago

    Aldeyra Therapeutics Presents Noninfectious Anterior Uveitis Phase 2 Clinical Trial Data to the American Uveitis Society Held at the American Academy of Ophthalmology 2017 Annual Meeting

    LEXINGTON, Mass., Nov. 29, 2017 /PRNewswire/ -- Aldeyra Therapeutics, Inc. (ALDX) ("Aldeyra"), a clinical-stage biotechnology company devoted to treating inflammation, inborn errors of metabolism, and other diseases related to endogenous aldehyde toxicity, presented new statistical analyses of the results of a randomized, multi-center, investigator-masked, comparator-controlled, parallel-group Phase 2 clinical trial of topical ocular reproxalap (formerly known as ADX-102), a first-in-class aldehyde sequestering agent, to the American Uveitis Society held at the American Academy of Ophthalmology 2017 Annual Meeting. The results of the analyses demonstrated formal statistical non-inferiority (p=0.036 after two weeks of therapy, p=0.048 after four weeks of therapy) of 0.5% reproxalap ophthalmic solution to Pred Forte®, a topical ocular corticosteroid, in reducing anterior chamber inflammatory cell count, the standard noninfectious anterior uveitis clinical endpoint.

  • Does Aldeyra Therapeutics Inc’s (ALDX) Debt Level Pose A Serious Problem?
    Simply Wall St.6 months ago

    Does Aldeyra Therapeutics Inc’s (ALDX) Debt Level Pose A Serious Problem?

    Aldeyra Therapeutics Inc (NASDAQ:ALDX) is a small-cap stock with a market capitalization of USD $113.75M. While investors primarily focus on the growth potential and competitive landscape of the small-cap companies,Read More...

  • PR Newswire6 months ago

    Aldeyra Therapeutics Announces Third Quarter 2017 Financial Results

    LEXINGTON, Mass. , Nov. 9, 2017 /PRNewswire/ -- Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) ("Aldeyra" or "the Company"), a clinical-stage biotechnology company devoted to treating inflammation, ...

  • PR Newswire7 months ago

    Aldeyra Therapeutics to Present at the Stifel 2017 Healthcare Conference

    LEXINGTON, Mass. , Nov. 7, 2017 /PRNewswire/ -- Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) ("Aldeyra" or "the Company"), a clinical-stage biotechnology company devoted to treating inflammation, ...

  • PR Newswire7 months ago

    Aldeyra Therapeutics Schedules Webcast and Conference Call to Provide Third Quarter 2017 Financial Results

    LEXINGTON, Mass. , Nov. 2, 2017 /PRNewswire/ -- Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) (Aldeyra), a clinical-stage biotechnology company devoted to treating inflammation, inborn errors of metabolism, ...

  • PR Newswire7 months ago

    Aldeyra Therapeutics Announces New Data at 2017 Research & Development Day

    LEXINGTON, Mass., Oct. 10, 2017 /PRNewswire/ -- Aldeyra Therapeutics, Inc. (ALDX) ("Aldeyra" or "the Company"), a clinical-stage biotechnology company devoted to treating inflammation, inborn errors of metabolism, and other diseases related to endogenous aldehyde toxicity, announced new clinical data for ADX-102 from recently completed Phase 2 clinical trials of dry eye disease and allergic conjunctivitis, and the introduction of a retinal disease development program with ADX-103, a novel aldehyde trap. "These newly released results from our Phase 2 clinical trials in dry eye disease and allergic conjunctivitis strongly support the broad and clinically relevant activity profile of ADX-102 in ocular inflammatory disease," commented Todd C. Brady, M.D., Ph.D., President and Chief Executive Officer of Aldeyra.

  • PR Newswire8 months ago

    Aldeyra Therapeutics Announces Presentation of Novel Data on the Efficacy of ADX-102 in a Model of Succinic Semialdehyde Dehydrogenase Activity at the 2017 American Society of Human Genetics Annual Meeting

    LEXINGTON, Mass., Oct. 5, 2017 /PRNewswire/ -- Aldeyra Therapeutics, Inc. (ALDX) (Aldeyra), a clinical-stage biotechnology company devoted to treating inflammation, inborn errors of metabolism, and other diseases related to endogenous aldehyde toxicity, today announced it will present novel data on the efficacy of ADX-102 in a model of Succinic Semialdehyde Dehydrogenase Deficiency (SSADHD) at the 2017 American Society of Human Genetics Annual Meeting, to be held on October 17 - 21 in Orlando, Florida. SSADHD is a rare inborn error of aldehyde metabolism caused by elevations of succinic semialdehyde, a toxic aldehyde that can lead to severe neurological disability.  By trapping succinic semialdehyde, ADX-102 represents a potential novel approach for the treatment of SSADHD. The novel aldehyde trap ADX-102 reduces accumulations of GHB and GABA in brain tissue from succinic semialdehyde dehydrogenase-deficient mice.

  • Aldeyra Therapeutics Inc (ALDX): How Does It Impact Your Portfolio?
    Simply Wall St.8 months ago

    Aldeyra Therapeutics Inc (ALDX): How Does It Impact Your Portfolio?

    If you are looking to invest in Aldeyra Therapeutics Inc’s (NASDAQ:ALDX), or currently own the stock, then you need to understand its beta in order to understand how it canRead More...

  • PR Newswire8 months ago

    /C O R R E C T I O N -- Aldeyra Therapeutics, Inc./

    In the news release, Aldeyra Therapeutics Announces 2017 Research and Development Day, issued 27-Sep-2017 by Aldeyra Therapeutics, Inc. over PR Newswire, we are advised by the company that the date in the second paragraph should read "Tuesday, October 10, 2017" rather than "Monday, October 10, 2017" as originally issued.